Regular Output from the ReMuS Registry

Data export updated on 31. 12. 2021
– Summary of Output from Analysis

In Prague, 5th April 2022
Description of the ReMuS Registry

Czech National Registry of Multiple Sclerosis (ReMuS) was mainly created to obtain data on the prevalence, incidence, severity at the time of diagnosis and clinical course of multiple sclerosis (MS), its clinical symptoms, relapses, progression, MS treatment, disability development, comorbidities and causes of death. The objective is to provide outputs for cost and effectiveness monitoring of health care and medicinal products, assessment of information to be provided to health care payers, other public institutions and manufacturers of medicinal products, to assess the seriousness of MS and its socioeconomic impacts from the scientific, epidemiologic and statistical perspective.

Based on acquired data, it will be possible to look for potential risk factors both for the development of MS itself and lack of effectiveness of treatment or more rapid progression of the disease. Information on course of MS will enable health care payers to plan better the allocation of financial means necessary for the treatment of this disease. Information on treatment effectiveness is instrumental in the selection of the therapy and implementation of changes or modifications when relevant.

The ReMuS registry does not distinguish whether patients are in a study or not. The registry now includes multiple sclerosis patients who:

- undergo treatment in one of the participating MS treatment centres
- have signed informed consent with processing their personal and clinical data in the ReMuS registry.

The detailed analysis includes patients who attended their appointment within the second half of 2021 (or within the last year in case of non-DMD patients) only. The analysis is presented in two sections. The main part covers DMD/IVIG patients and has an identical structure for all centres. The second part summarizes preliminary results for non-DMD patients and is present for MS centres which entered the non-DMD patients into the registry only.

On 31. 12. 2021, the 18th data export into ReMuS registry was delivered, followed by 15th regular interim data analysis from the registry focusing on the year 2021. Over the evaluated period data of DMD patients from 15 MS treatment centres - General University Hospital in Prague (VFN), Hospital Teplice (TP), Hospital Jihlava (JI), Motol University Hospital in Prague (FNM), University Hospital Plzeň (FNP), Hospital of Pardubice Region (PA), University Hospital Ostrava (OV), University Hospital Královské Vinohrady in Prague (FNKV), University Thomayer Hospital in Prague (FTN), University Hospital Hradec Králové (HK), University Hospital in Brno Bohunice (FNB), University Hospital Olomouc (OL), České Budějovice Hospital (CB), St. Anne’s University Hospital in Brno (USA) and Regional Hospital T. Baťa in Zlín (ZL) were included. Information about non-DMD patients was provided by 15 MS centres with at least 20 non-DMD patients with recent data. All centres enter data on their patients in the registry on continual basis, and as of the day of export on 31. 12. 2021 data on the treatment of 14 419 DMD patients and 4 618 non-DMD patients has been collected. After the exclusion of patients missing recent data, data of the total of 13 845 DMD and 3 303 non-DMD patients from the whole Czech Republic were processed for the purpose of the present analysis.

For the main analysis, data of patients with current data available and treated in the last year with one of the DMD medication were included. DMDs: Aubagio, Avonex, Betaferon, Copaxone, Copaxone [40], Extavia, Generics of Mabthera (Rixathon, Truxima), Gilenya, Kesimpta, Lemtrada, Mabthera, Mavenclad, Mayzent, Ocrevus, Plegridy, Ponvory, Rebif [22], Rebif [44], Tecfidera, Tysabri, Zeposia.

Patients in the registry were in 70.8% of cases of female gender, mean age at the last visit was 43.6 years and the mean age at the disease onset was 31.8 years. A total of 99.6% patients were over 18 years old at the time of the last visit. The registry included data of patients from all regions of the Czech Republic. A total of 78.1% patients up to 65 years of age were able to work (they worked full time or part-time) and 31.9% received stage 1-3 disability pensions. The most frequent degree of damage impairment were patients with EDSS 1.5. Mean number of relapses in one year (ARR, annualized relapse rate) was 0.181. Medication used the most often was Copaxone (17.4%). During the last year, 5.0% of patients initiated their first DMD treatment, 2.4% of patients reinitiated the same DMD treatment after discontinuation, a total of 8.9% switched to another DMD treatment and 2.3% of patients ended or interrupted the DMD treatment. A total of 0.2% patients were treated by IVIG treatments. In 2021 a total of 185 MS female patients (1.9%) delivered children.

Patients classified as “non-DMD” are also included into the present analysis for centres with such data available. These patients had been treated with DMD in the last year or haven’t used these products at all. Non-DMD patients were described in terms of demography, working activity, social benefits, duration of the treatment, EDSS, frequency of relapses and pregnancy. Data from all 15 MS centres which were contributing were processed. The mean age of non-DMD patients was higher than in DMD patients (55.0 years vs. 43.6 years) and they appeared to be elder at the onset of the disease (35.0 years vs. 31.8 years). Notably smaller portion of non-DMD patients up to 65 years were working. Non-DMD patients in the registry had higher mean EDSS compared to DMD patients (4.7 vs. 2.7) whilst the most frequent non-DMD patients were those with EDSS stage 6.5 (18.3%). A total of 6.2% non-DMD patients experienced relapses in 2021. In the last year a total of 10 non-DMD female patients (0.4%) delivered children. A total of 7.5% patients were treated by IVIG treatments.

Progressive engagement of the individual centres and gradual increase in the number of patients needs to be considered for interpretation of the outcomes. The records are continuously corrected and amended based on the deviation reports in all participating centres. Compared to the first data export in June 2013, the number of missing data has now decreased and with participation of new centres the variability of patients and their treatment in the Czech Republic increased.